Physician profile
Robert John Cole
NPI 1043482342
$806.91
in general payments reported to CMS, 2019-2025
15 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $14.83 · 2021: $148 · 2022: $55.11 · 2023: $40.89 · 2024: $141 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $372.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $206.19 | 2019-2025 | |
| Sirtex Medical INC | $147.81 | 2021 | |
| Amarin Pharma, INC. | $124.85 | 2019 | |
| Merck Sharp & Dohme LLC | $57.87 | 2019 | |
| Janssen Biotech, INC. | $37.60 | 2025 | Erleada, Darzalex, Talvey |
| Palette Life Sciences, INC. | $34.92 | 2022 | |
| Novocure INC. | $34.25 | 2025 | Optune Gio |
| Astrazeneca Pharmaceuticals Lp | $32.38 | 2024 | |
| Reflexion Medical, INC. | $22.92 | 2024 | Reflexion Medical Radiotherapy System |
| Genzyme Corporation | $21.17 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.23 | 2025 | |
| Daiichi Sankyo INC. | $19.00 | 2024 | Vanflyta |
| Regeneron Healthcare Solutions, INC. | $16.39 | 2025 | Lynozyfic |
| Incyte Corporation | $16.32 | 2024 | Jakafi |
| Lilly USA, LLC | $16.01 | 2025 | Jaypirca, Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.